Clinical trial

Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

NCT07436663

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-02-01

PhasePHASE4

Study timeline

Study start (estimated)2026-02-01Date precision: day

Registry last updated2026-02-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor TherapyDRUG

Sitagliptin (DPP4 inhibitor)DRUG

Standard Care (in control arm)OTHER

Sponsors & collaborators

Tanta Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07436663 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.